Torii Pharmaceutical Co., Ltd. (TRXPF)

24.57 0.00 (0.00%) At close: 02:13PM EDT

Torii Pharmaceutical Co., Ltd.

Torii Nihonbashi Bldg.
4-1, Nihonbashi-Honcho 3-chome Chuo-ku
Tokyo 103-8439
Japan
81 3 3231 6811
https://www.torii.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 583

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Goichi Matsuda	President, CEO & Representative Director	N/A	N/A	1967
Yukihiro Takashima	General Manager of Finance & Accounting Department	N/A	N/A	N/A
Mr. Masaki Sunami	Executive Officer, Head of Production Group & Production Group Leader	N/A	N/A	N/A
Mr. Atsuyuki Kakee	Managing Executive Officer, Leader of Value Creation Group & GM of Business Development Department	N/A	N/A	N/A
Mr. Katsunobu Fujiwara	Managing Executive Officer & Pharmaceutical Sales Group Leader	N/A	N/A	N/A
Mr. Nobumasa Kondo	Managing Executive Officer & Planning and Support Group Leader	N/A	N/A	1968
Noriaki Nishino	Executive Officer, Head of Pharmacovigilance & Quality Assu Grp and Quality Assurance Grp Leader	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.

Corporate governance

Torii Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.